中国での胃癌ステージ2治療—3つのパーソナライズクリニックマッチングを取得

The standard surgical procedure for Stage 2 stomach cancer in China is radical gastrectomy combined with D2 lymphadenectomy. Surgeons perform either subtotal or total stomach removal based on tumor location. This procedure follows Chinese Society of Clinical Oncology guidelines to ensure complete tumor clearance and extensive lymph node harvest.

• Resection type: Distal gastrectomy removes lower stomach portions while total gastrectomy removes the entire organ.
• Lymphadenectomy standard: D2 dissection removes perigastric and second-tier lymph nodes along major abdominal arteries.
• Node harvest: Specialized high-volume Chinese centers typically harvest over 30 lymph nodes for accurate staging.
• Surgical approach: JCI-accredited facilities like Fuda Cancer Hospital utilize minimally invasive laparoscopic or robotic techniques.

Bookimed Expert Insight: Chinese oncology centers demonstrate a high capacity for complex cases, with Fuda Cancer Hospital serving over 30,000 international patients. Clinical patterns show that centers in Guangzhou and Xiamen prioritize multidisciplinary teams. These teams often integrate cryosurgery or NanoKnife technologies for cases where traditional surgery requires additional local control.

Patient Consensus: Patients emphasize that final pathology reports after surgery often lead to adjustments in the treatment plan. They note it is vital to prepare for significant dietary changes and nutritional adaptation following a total gastrectomy.

Chemotherapy is common for stage 2 stomach cancer but not always mandatory after surgery. Neoadjuvant chemotherapy before surgery is standard for shrinking tumors to improve resection success. Adjuvant chemotherapy after surgery eliminates microscopic cells. The decision depends on lymph node status and tumor depth found during resection.

• Neoadjuvant therapy: Administered before surgery to shrink aggressive tumors and ensure cleaner margins.
• Adjuvant therapy: Used after surgery to reduce the risk of cancer returning to the stomach.
• Pathology factors: Lymph node positivity or high-grade cells often trigger postoperative chemotherapy requirements.
• Treatment flexibility: Chinese oncology centers like Fuda Cancer Hospital utilize minimally invasive therapies alongside chemotherapy.

Bookimed Expert Insight: Patient data suggests that recovery speed often dictates the chemotherapy timeline. Fuda Cancer Hospital serves over 30,000 international patients and focuses on minimally invasive alternatives. If postoperative weight loss is severe, doctors may prioritize recovery before starting heavy drug cycles to ensure patient safety.

Patient Consensus: Patients note that stage 2 treatment plans vary. Some undergo surgery first while others start with chemo to control tumor spread. Many emphasize that post-surgical eating difficulties can make starting chemotherapy challenging.

Chinese hospitals primarily prescribe fluoropyrimidine and platinum-based doublet therapies for Stage 2 stomach cancer. The Chinese Society for Clinical Oncology guidelines recommend these after D2 gastrectomy. Standard regimens include SOX, XELOX, and FOLFOX. These protocols reduce recurrence risks and target microscopic spread.

• SOX regimen: Combines oral S-1 with intravenous oxaliplatin for 3-week cycles.
• XELOX protocol: Also known as CAPOX, using capecitabine plus intravenous oxaliplatin.
• FOLFOX therapy: An all-intravenous option for patients unable to take oral medications.
• Integrative approach: Hospitals often add Traditional Chinese Medicine to manage side effects.

Bookimed Expert Insight: Clinical practice in China shows a strong preference for the SOX regimen. It is more common here than in Western countries. This is because S-1 is specifically effective in East Asian populations. Patients should ensure their nutritional status is stable. Doctors at clinics like Fuda Cancer Hospital adjust doses based on body weight. This flexibility helps patients complete the full course safely.

Patient Consensus: Patients note that doctors prioritize oxaliplatin-based doublets as the modern standard. Many emphasize that dose adjustments or treatment delays are routine to manage nutrition and lab values.

International patients at top Chinese oncology centers typically see 5-year survival rates between 63% and 86% for Stage 2 stomach cancer. These rates reflect outcomes from high-volume urban institutions. Success depends on radical D2 gastrectomy and adjuvant chemotherapy. Advanced molecular profiling further improves these benchmarks.

• Stage IIA benchmark: National Cancer Center data indicates 86.5% survival for pathological Stage IIA.
• Stage IIB benchmark: Elite hospital cohorts report a 76.1% 5-year survival rate for Stage IIB.
• Neoadjuvant impact: Patients receiving chemotherapy before surgery show a 63.2% 5-year survival rate.
• Surgical volume: Specialists at centers like Fuda Cancer Hospital utilize high-volume expertise for complex resections.

Bookimed Expert Insight: Survival data in China is heavily influenced by surgical specialization. Facilities like Fuda Cancer Hospital have served over 30,000 patients from 100 countries. This massive volume often leads to better outcomes in complex D2 lymphadenectomies. Patients should prioritize hospitals with JCI accreditation to ensure international pathology and safety standards are met.

Patient Consensus: Patients note that survival depends on achieving clear surgical margins and adequate lymph node removal. Many emphasize that long-term recovery requires proactive management of nutrition, B12 levels, and post-operative weight loss.

International patients usually stay in China for 3 to 6 months for complete Stage 2 stomach cancer treatment. This period covers specialized surgery like radical D2 gastrectomy and multiple rounds of adjuvant chemotherapy. JCI-accredited facilities in cities like Guangzhou provide these integrated oncology protocols.

• Pre-treatment phase: MDT consultations and staging tests require approximately 1 week.
• Surgical admission: Hospital stays for gastrectomy usually last 10 to 14 days.
• Local recovery: Patients need 4 to 5 weeks for post-operative dietary adjustment.
• Chemotherapy cycles: Adjuvant regimens like XELOX often span 3 to 5 months.

Bookimed Expert Insight: Patients can optimize their stay by choosing clinics like Fuda Cancer Hospital. This facility specializes in minimally invasive therapies that may serve as alternatives to traditional chemotherapy. Their experience with over 30,000 international patients ensures streamlined transitions between surgical recovery and local outpatient lodging.

Patient Consensus: Patients emphasize that recovery is measured in weeks rather than days. They recommend staying near the hospital after discharge to manage feeding issues or nutrition adjustments before flying home.

Chinese centers integrate Traditional Chinese Medicine (TCM) into Stage 2 stomach cancer protocols as supportive care. Major hospitals alongside Western oncology departments provide TCM to manage side effects. It never replaces the primary curative strategy of radical gastrectomy and adjuvant chemotherapy in JCI-accredited facilities.

• Surgical recovery: Doctors use herbal decoctions after gastrectomy to restore gastrointestinal function.
• Chemotherapy support: Herbal injections like Shenqi Fuzheng help protect against low white blood cell counts.
• Symptom management: Acupuncture and acupressure routinely reduce nausea, fatigue, and postoperative pain.
• Maintenance phase: Personalized prescriptions aim to prevent recurrence by regulating the body immune environment.

Bookimed Expert Insight: While many search for alternative cures, Chinese oncology centers like Fuda Cancer Hospital emphasize a multidisciplinary approach. They combine Western surgery with advanced technologies like cryosurgery or NanoKnife rather than TCM alone. Our data shows these integrated centers favor TCM specifically for post-operative recovery blocks to help patients tolerate intensive chemotherapy.

Patient Consensus: Patients note that TCM is most effective for regaining their appetite and bowels after major stomach surgery. They often warn others to ensure that herbal therapies do not delay the necessary surgical staging or chemotherapy schedule.

Immunotherapy and targeted agents are not standard for Stage 2 stomach cancer in China. Most Chinese clinical protocols prioritize radical D2 surgery and cytotoxic chemotherapy. These advanced therapies are typically reserved for Stage 4 metastatic disease or specifically documented recurrence cases.

• Surgical standard: Radical D2 gastrectomy remains the primary curative treatment for resectable cases.
• Chemotherapy protocols: Adjuvant platinum doublet regimens like SOX or XELOX follow surgical resection.
• Biomarker testing: Targeted agents require positive markers like HER2 or Claudin 18.2 for use.
• Clinical trials: Participation in trials is the main route for early-stage immunotherapy access.

Bookimed Expert Insight: While Stage 2 standard care is surgery-focused, specialized centers like Fuda Cancer Hospital utilize over 10 types of minimally invasive therapies. These technologies, including NanoKnife and cryosurgery, provide localized alternatives to systemic drugs. This is particularly valuable for patients who cannot tolerate aggressive chemotherapy after their gastrectomy.

Patient Consensus: Patients note that D2 surgery is the expected first step. Many emphasize asking for biomarker tests early to identify long-term options if the cancer recurs.